【24h】

Management of hereditary antithrombin deficiency in pregnancy

机译:妊娠期遗传性抗凝血酶缺乏的管理

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Antithrombin (AT) deficiency is a high-risk thrombophilia and a rare condition. Despite full anticoagulation during pregnancy and the postpartum period, women with AT deficiency may still be vulnerable to developing venous thromboembolism (VTE), including fatal events. There is limited guidance on the management of AT deficiency in pregnancy, including the role of AT concentrates. Following a comprehensive review of the state of the art with respect to recommendations and guidelines, our expert panel in maternal-fetal medicine, hematology and basic science reached consensus on key issues in the recognition andmanagement of AT deficiency in pregnancy. This paper summarizes the state of the art and summarizes what we believe are best practices with special emphasis on a multidisciplinary approach involving obstetrics and hematology in the care of womenwith AT deficiency. (C) 2017 Elsevier Ltd. All rights reserved.
机译:抗凝血酶(AT)缺乏是一种高危血栓性和罕见的病症。 尽管在怀孕期间和产后期间完全抗凝,但缺乏症的妇女仍然可能易于发展静脉血栓栓塞(VTE),包括致命事件。 对怀孕缺乏的管理有限的指导,包括在浓缩物中的作用。 在关于艺术态度的全面审查关于建议和准则的情况下,我们的孕产妇医学,血液学和基础科学专家小组达成了对怀孕缺陷识别和管理者的关键问题的共识。 本文总结了艺术的状态,总结了我们认为是特别强调涉及在缺乏缺陷的女性妇女妇女的多学科方法的最佳实践。 (c)2017 Elsevier Ltd.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号